Welcome!

News Feed Item

Panther Biotechnology, Inc. Announces the Appointment of Two Directors and Securing an Option on a Potential Blockbuster Novel Oncology Small Molecule With Northwestern University That Panther Will Fast Track Into the Clinic

CHICAGO, IL -- (Marketwired) -- 08/26/14 -- Panther Biotechnology, Inc. (OTCQB: PBYA) announced today the appointments of Mr. David Barshis and Mr. James Sapirstein to the company's Board of Directors. In addition the Panther announced it has secured an option agreement on a license for its lead technology, Numonafide a potential blockbuster novel small molecule compound in the liquid and solid tumor cancer market place, with Northwestern University.

Mr. Barshis has over twenty-five year's entrepreneurial experiences in organizing and managing life science ventures in the U.S. and internationally. He has developed multiple start-up companies from the ground up and developed them into publicly traded entities on the U.S. and Canadian stock exchanges. Mr. Sapirstein brings over thirty years of pharmaceutical industry experience to the Company having served in various roles in research, development and sales. More recently James served as Chief Executive Officer to a number of biotechnology and healthcare companies from start-ups to fully operational and profitable entities. Full biographies are posted on the Company's web site www.pantherbiotechnology.com.

Irwin Zalcberg, Chairman of Panther, commented, "With the additions of David and James we have advanced our goals of organizing a team necessary to oversee, evaluate and assist in the execution of our plans to begin to develop important cancer treatments and shepherd these treatments through early and later stage clinical studies. Adding the strong backgrounds in research, clinical development, management and pharmaceutical industry expertise we feel we are poised to move Panther into a fully functioning drug development company."

In addition the Company is announcing it has secured an option on a license and is working on finalizing the formal license for its lead technology candidate, Numonafide, from Northwestern University. Numonafide, a derivative of the widely studied drug Amonafide, is a DNA intercalator and topoisomerase 2 inhibitor. Through research completed at Northwestern University this derivative has shown to compose all of the positive cancer inhibitory abilities of Amonafide while avoiding the toxic metabolism demonstrated with the Drug. Dr. Jayesh Mehta, M.D. Director of Panther, commented, "We have been evaluating the positive in-vitro and in-vivo results being achieved with this technology and are looking to accelerate its development into human clinical studies. We look forward to partnering with Northwestern University to complete pre-clinical development activities and prepare this drug for introduction to patients."

Panther Biotechnology, Inc.

Panther Biotechnology is a newly formed entity focused on the acquisition and development of therapeutics for the treatment of leukemia, lymphoma, myeloma and other cancers. The Company will focus on identifying promising anti-cancer therapeutic candidate that are optimized derivatives of widely studied products or re-purposed existing marketed compounds. The first product candidate, Numonafide, will be evaluated for the treatment of patients with Acute Myeloid Leukemia (AML). The AML market is anticipated to grow to $1.67 billion dollars by 2020 in G8 countries and it is Panthers belief that there are insufficient treatment options available to treat patients.

Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Panther cannot ensure that it will be able to achieve a license for Numonafide on a commercially acceptable or reasonable basis and may not be able to attract the necessary funding to advance the project in a timely manner. In addition, Panther cannot ensure that clinical results related to in-vivo and in-vitro studies of Numonafide will reproduce the positive results achieved to date. Finally, Panther cannot be sure that it will be able to obtain regulatory approval for the commercial marketing of its treatment for Patients with AML and there may be other treatments in development that are approved before Panthers.

Contact:
Richard P. Rainey
Chief Executive Officer
(570) 343-9867


More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infrastructure through automation. Ayehu solutions have been deployed by major enterprises worldwide, and currently, support thousands of IT processes across the globe. The company has offices in New York, California, and Isr...
Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said "No to LUNs." With Tintri they manage only virtual machines, in a fraction of the footprint and at far lower cost than conventional storage. Tintri offers the choice of all-flash or hybrid-flash platform, converged or stand-alone structure and any hypervisor. Rather than obsess with storage, leaders focus on the business app...
Addteq is one of the top 10 Platinum Atlassian Experts who specialize in DevOps, custom and continuous integration, automation, plugin development, and consulting for midsize and global firms. Addteq firmly believes that automation is essential for successful software releases. Addteq centers its products and services around this fundamentally unique approach to delivering complete software release management solutions. With a combination of Addteq's services and our extensive list of partners,...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
SYS-CON Events announced today that IoT Now has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...